Literature DB >> 3026186

Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS.

K Henry, H Cantrill, C Fletcher, B J Chinnock, H H Balfour.   

Abstract

A patient with acquired immune deficiency syndrome with bilateral cytomegalovirus retinitis was treated with intravitreal 200-micrograms/0.1-ml doses of ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl]guanine). The ganciclovir serum and intravitreal concentrations were measured with an enzyme-linked immunosorbent assay and pharmacokinetic factors were determined. There was no evidence of systemic absorption of ganciclovir from the eye. The elimination half-life of ganciclovir from the vitreous was estimated to be 13.3 hours. The intravitreal concentration remained above the ID50 of cytomegalovirus for approximately 62 hours after a single injection. Clinically, the patient retained useful vision in his right eye for three months. A total of 28 intravitreal injections were given on an outpatient basis under topical anesthesia and were well tolerated. There was no evidence of retinal toxicity from the drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3026186     DOI: 10.1016/s0002-9394(14)74163-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  34 in total

Review 1.  New developments in sustained release drug delivery for the treatment of intraocular disease.

Authors:  G Velez; S M Whitcup
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 2.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

3.  Treatment of cytomegalovirus retinitis: A growing number of options.

Authors:  S D Shafran; J M Conly
Journal:  Can J Infect Dis       Date:  1996-11

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 5.  Oncology.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

6.  Intravitreal therapy with ganciclovir for posterior pole cytomegalovirus retinitis in AIDS patients.

Authors:  J Orellana; R M Lieberman; R Peairs; S Restreppo
Journal:  Br J Ophthalmol       Date:  1990-08       Impact factor: 4.638

7.  Intravitreal ganciclovir in CMV retinitis: case report.

Authors:  M L Harris; M B Mathalone
Journal:  Br J Ophthalmol       Date:  1989-05       Impact factor: 4.638

8.  Intravitreal liposome-encapsulated drugs: a preliminary human report.

Authors:  G A Peyman; H C Charles; K R Liu; B Khoobehi; M Niesman
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

9.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

10.  Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial.

Authors:  M Díaz-Llopis; M J Martos; E España; M Cervera; A O Vila; A Navea; F J Molina; F J Romero
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.